Overview

Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer

Status:
Not yet recruiting
Trial end date:
2028-06-30
Target enrollment:
Participant gender:
Summary
To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborator:
Ludwig Institute for Cancer Research